Poster
Focal Radiation Enhances Paclitaxel Therapy in a Mouse Model of Triple Negative Breast Cancer
![](https://content.labcorp.com/sites/default/files/biopharma_knowledge_library/posters/Focal-Radiation-Enhances-Paclitaxel-Therapy-in-a-Mouse-Model-of-Triple-Negative-Breast-Cancer-Poster.pdf.png)
AACR 2017 -- Triple negative breast cancer (TNBC) accounts for 15-20% of all breast cancers in the United States. Patients with TNBC have poorer prognosis and therapeutic intervention is more challenging due to insensitivity to hormonal and anti-HER2 therapies. Therapeutic options for TNBC can include chemotherapy and/or radiation (RT) treatment.